Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sarepta TherapeuticsMEX:SRPT 36 Days Payable is 37.78 as of Jun. 2026, which is 88% below its 10-year median of 322.65. GuruFocus rates MEX:SRPT with a GF Score™ of 36/100 and a GF Value™ of MXN1,547.44 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 708 Biotechnology companies, Sarepta Therapeutics ranks worse than 65.11% on this metric.
The historical rank and industry rank for Sarepta Therapeutics's Days Payable or its related term are showing as below:
MEX:SRPT'
s Days Payable Range Over the Past 10 Years
Min: 57.21 Med: 322.65 Max: 90209.21
Current: 57.21
During the past 13 years, Sarepta Therapeutics's highest Days Payable was 90209.21. The lowest was 57.21. And the median was 322.65.
MEX:SRPT's Days Payable is ranked worse than 65.11% of 708
companies
in the Biotechnology industry
Industry Median: 111.165
vs MEX:SRPT: 57.21
Sarepta Therapeutics's Days Payable
declined
from Jun. 2025 (91.61) to Jun. 2026 (37.78).
It may suggest that Sarepta Therapeuticsaccelerated paying its suppliers.
The historical data trend for Sarepta Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:SRPT vs MPLT, ZYME, ABCL: Days Payable Comparison
For the Biotechnology subindustry, Sarepta Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sarepta Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Sarepta Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sarepta Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sarepta Therapeutics (MEX:SRPT) has a Days Payable of 37.78 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sarepta Therapeutics and its competitors. This is 88% below median its historical median of 322.65. Over the past decade, Sarepta Therapeutics' Days Payable has ranged from 57.21 to 90,209.21. According to the industry distribution chart, Sarepta Therapeutics ranks #461 out of 708 companies in the Biotechnology industry, placing it in the top 65.1%.
Is Sarepta Therapeutics' Days Payable too high?
Sarepta Therapeutics' current Days Payable of 37.78 is 88% below median its 10-year median of 322.65. Over the past 10 years, this metric has ranged from a low of 57.21 to a high of 90,209.21. The Biotechnology industry median Days Payable is 111.17. Sarepta Therapeutics' value of 37.78 is 66% below this industry median. Based on the distribution chart, Sarepta Therapeutics ranks #461 out of 708 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sarepta Therapeutics has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Days Payable compare to MPLT and ZYME?
According to the Biotechnology industry distribution chart, Sarepta Therapeutics ranks #461 out of 708 companies for Days Payable. This places Sarepta Therapeutics in the lower half of its industry. The industry median Days Payable is 111.17. Sarepta Therapeutics' value of 37.78 is 66% below this benchmark. Historically, Sarepta Therapeutics' own Days Payable has ranged from 57.21 to 90,209.21 over the past decade. While the company's 10-year median is 322.65 vs. the industry median of 111.17, Sarepta Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.17, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sarepta Therapeutics's current Days Payable of 37.78 is 66% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sarepta Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 111.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sarepta Therapeutics's current Days Payable is 37.78, which is 88% below median its own 10-year median of 322.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (MEX:SRPT) is currently considered Possible Value Trap. The stock's GF Value™ is MXN1,547.44, compared to a current price of MXN306.00 — trading 80.2% below its estimated fair value. The current Days Payable is 37.78, which is 88% below median its 10-year median of 322.65 and 66% below the Biotechnology industry median of 111.17. Sarepta Therapeutics' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sarepta Therapeutics (MEX:SRPT), the current Days Payable is 37.78 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sarepta Therapeutics (MEX:SRPT) Overvalued in 2026?
Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued.
The current stock price of MXN306.00 is trading 80.2% below its estimated GF Value™ of MXN1,547.44.
GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.
Key valuation signals for MEX:SRPT:
Days Payable: 37.78 (88% below median its 10-year median of 322.65)
GF Value™: MXN1,547.44 vs. price of MXN306.00 (80.2% below fair value)
Industry Position: 66% below the Biotechnology median (#461 of 708)
No single metric tells the full story. See the MEX:SRPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
36GF Score
Get the complete analysis for MEX:SRPT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:SRPT has been successfully added to your 
